Another anti-EGFR monoclonal antibody, nimotuzumab, has shown promising results in a variety of solid tumors, such as head and neck neoplasm, non–small cell lung cancer, neuroglioma, and pancreatic cancer (34–37). This evidence concerns the gene EGFR and familial pancreatic carcinoma.